Seattle, WA, Aug-12, 2018 — / True Industry News / —
Demand for gene therapy is significantly increasing due to increasing number of patients suffering from hereditary disorders, cancer, HIV, and various chronic diseases. For instance, 2018 American Cancer Society report showed cancer was responsible for 609,640 deaths in the U.S. Moreover, in 2017, WHO reported 1.0 million deaths were caused due to HIV-related illnesses worldwide. Increasing technological developments, innovations, and clinical and pre-clinical trials.
For instance, According to published article in 2014 Regenerative Medicine reports 4749 registries of clinical trials related to stem cell treatment. Several diseases are likely to propel growth of the gene therapy market size during the forecast period. Moreover, increasing research and development funding by government agencies and commercial market players for the development of innovative, efficient, and safer gene therapy practices is boosted the market growth. For instance, 2017 National Institutes of Health was funded US$ 1,644 million for stem cell research. Furthermore, growing awareness and community acceptance of gene therapy for various disease treatments is propelling growth of the market.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1774
Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with the help of gene therapy normal copy of that missing or faulty protein can be introduced to restore the function of the protein.
Key Vendors of Gene Therapy Market: Key players operating in the global gene therapy market include GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc. These companies are conducting various clinical and pre-clinical developmental stages of gene therapies. Key players are engaged in developing new technologies and are focusing on collaborating with leading companies in order to retain their foothold in the global market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved a gene therapy called Luxturna, developed by Spark Therapeuticsa Biotech Company based in Philadelphia.
On the basis of gene therapy type, the global gene therapy market is segmented into: Germline Gene Therapy, Somatic Gene Therapy,.
On the basis of type of vector, the global gene therapy market is segmented into: Viral Vector, Non-viral Vector,.
On the basis of disease indication, the global gene therapy market is segmented into: Cardio Vascular Diseases, Cancer, Genetic Disorders, Neuro Disorders, Infectious Diseases, Others,.
Request TOC of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1774
On the basis of geography, the global gene therapy market is segmented into: North America, Latin America, Europe, Asia Pacific, Middle East, Africa,.
Key questions answered in Gene Therapy market report:
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1774